Role Of Non-Specific Effects in The Treatment of Depression With Esketamine
- Conditions
- Depressive Episode
- Registration Number
- NCT05910775
- Lead Sponsor
- Yale University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria:<br><br> - Participants must be either male or female and at least 18 years old<br><br> - Deemed clinically appropriate to receive esketamine by a Yale Interventional<br> Psychiatry physician.<br><br> - Written consent for the study procedures<br><br> - Ability and willingness, in the investigator's judgement, to comply with the study<br> schedule, treatment plan, and other trial requirements for the duration of the<br> study.<br><br>Exclusion Criteria:<br><br> - Hearing or visual impairment to the degree that would interfere with ability to view<br> the presentation<br><br> - Difficulty in understanding spoken or written English<br><br> - Unable to provide informed consent<br><br> - Dementia or other cognitive disorder or intellectual disability that would impair<br> the subject's ability to understand the presentation (per investigator judgment)<br><br> - Any other medical or psychiatric comorbidity that the investigator judges would put<br> the participant at additional undue risk due to study participation or would impair<br> subject's ability to participate in the study.<br><br> - Previous Esketamine or ketamine treatment<br><br> - Unable to give informed consent<br><br> - Was previously enrolled/randomized into the trial
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Group difference in change in question 6 score on Treatment Credibility and Expectancy Scale (CEQ-6)
- Secondary Outcome Measures
Name Time Method Group difference in change in Montgomery-Åsberg Depression Rating Scale (MADRS) score